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the progression of ventricular dysfunction. In patients with severe
CAD, production and release of endothelin, angiotensin II and
activation of neurohormonal systems lead to direct stimulation of
interstitial fibrosis, contributing to the pathophysiology of heart
failure (6,7).
Thus, two distinct types of ischemic CMP could be separated:
ischemic post-MI CMP and ischemic non–post-MI CMP. These
entities have dissimilar prevalence, incidence, natural history and
could require a dissimilar therapeutic approach.
Obviously, the majority of ischemic non–post-MI CMP is
found among patients with severe CAD, LV dysfunction and
congestive heart failure in absence of history of MI. Unfortunately,
Felker et al. (1) did not report the proportion of patients with
ischemic CMP but without history of MI in their population. It
would be of interest to disclose these data.
The main pitfall in the differential diagnosis between ischemic
post-MI and non–post-MI cardiomyopathies in the clinical setting
is related to cases with silent MI in the past. For clinical research
purposes, we propose that patients without a history of MI with
severe diffuse CAD on coronary angiography and significant global
LV dysfunction in absence of regional wall motion abnormalities
and/or scars on echocardiography should be considered as bearing
ischemic non–post-MI CMP. The recognition of this entity as a
different type of ischemic CMP is important for clinical trials and
population-based studies aiming to determinate the prevalence,
natural history and optimal therapeutic strategies for patients with
ischemic non–post-MI CMP.
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REPLY
We appreciate the interest of Drs. Tenenbaum, Fisman and Motro
in our study (1). We agree that there are likely to be important
subsets within the group of patients with ischemic cardiomyopathy
(CMP). As they point out, the characteristics and prognosis of
patients with heart failure as the result of myocardial infarction
(MI) may be different from patients with ischemic CMP and no
previous MI. We concur with their assertion that patients with
ischemic CMP and no prior MI are more likely to have hibernat-
ing myocardium, leading to progressive neurohormonal activation
and myocyte apoptosis if coronary blood flow is not restored.
In response to their inquiry, we reassessed our data to determine
the proportions of patients in the ischemic etiology group with and
without a history of previous MI. Sixty percent of the patients
classified as ischemic using our criteria had a prior MI. Compared
to patients in the ischemic group without prior MI, the MI group
had a significantly better unadjusted survival (49% vs. 32% at five
years, p  0.001). Survival for both groups was significantly worse
than that of the nonischemic patients (unadjusted survival of 60%
at five years). When history of MI was added to the multivariable
Cox proportional hazards model to adjust for other differences
between the groups, it had a protective effect with a hazard ratio of
0.72 (p  0.001).
One potential explanation for the seemingly paradoxical “pro-
tective effect” of a prior MI in patients with coronary artery disease
(CAD) and heart failure may relate to differences in the type of
coronary disease between the two groups. Even controlling for the
extent of CAD using the number of diseased vessels or the CAD
index cannot completely adjust for differences in the nature of the
CAD (focal vs. diffuse) and the likelihood and completeness of
revascularization. We hypothesize that patients with “ischemic
non–post-MI CMP” would be more likely to have diffuse coronary
disease not readily amenable to traditional revascularization tech-
niques, potentially explaining their worse outcomes. The upcom-
ing STICH trial may shed further light on the efficacy of various
surgical therapies in different subgroups of patients with heart
failure and CAD.
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